The REDUCE EU Study - Endobronchial Thermal Liquid Ablation (ETLA) for the Treatment of Emphysema

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 10, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

May 31, 2026

Conditions
Emphysema or COPDEmphysemaEmphysema, PulmonaryCOPDCOPD (Chronic Obstructive Pulmonary Disease)
Interventions
DEVICE

Endobronchial Therman Liquid Ablation (ETLA)

The ETLA System is a minimally invasive bronchoscopic treatment designed to deliver heated normal saline to targeted emphysematous lung regions with hyperinflation to cause tissue ablation and subsequent volume reduction as a means for treating emphysema. The ETLA procedures will be performed under general anesthesia. Each procedure will be limited to treatment in a single lung, with either unilateral or bilateral treatment over the two procedures.

Trial Locations (7)

1090

NOT_YET_RECRUITING

Universitätsklinikum Allgemeines Krankenhaus Wien, Vienna

1210

RECRUITING

Klinik Floridsdorf, Vienna

9700

NOT_YET_RECRUITING

University Medical Center Groningen, Groningen

14089

RECRUITING

Gemeinschaftskrankenhaus Havelhöhe gGmbH Klinik für Anthroposophische Medizin, Berlin

22307

NOT_YET_RECRUITING

Asklepios Klinik Barmbek, Hamburg

NOT_YET_RECRUITING

Thoraxklinik University of Heidelberg, Heidelberg

82131

NOT_YET_RECRUITING

Asklepios Lungenklinik Gauting GmbH, Gauting

All Listed Sponsors
lead

Morair Medtech, LLC

INDUSTRY